(PRVA) Privia Health - Overview
Sector: Healthcare | Industry: Health Information Services | Exchange: NASDAQ (USA) | Market Cap: 2.711m USD | Total Return: -5.8% in 12m
Avg Turnover: 21.5M
EPS Trend: 82.9%
Qual. Beats: 0
Rev. Trend: 96.6%
Qual. Beats: 0
Warnings
P/E ratio 126.5
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Altman Z'' 1.07 < 1.0 - financial distress zone
Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
Privia Health Group, Inc. (PRVA) is a physician-enablement company that provides technology and administrative infrastructure to independent medical practices and health systems. The company utilizes a single-Tax Identification Number (TIN) model, which allows disparate provider groups to consolidate their negotiating power and align financial incentives under a unified clinical framework.
The business model focuses on transitioning providers from traditional fee-for-service models to value-based care through its Accountable Care Organizations (ACOs). By managing population health data and reducing administrative burdens, Privia aims to lower healthcare utilization costs while improving patient outcomes. The physician-enablement sector is currently experiencing growth as independent practices seek scale to manage the increasing complexity of federal reimbursement regulations.
To further evaluate the companys competitive positioning and historical performance, consider reviewing the detailed metrics available on ValueRay.
- Physician network expansion drives recurring management services organization revenue growth
- Transition to value-based care contracts increases shared savings incentive potential
- Medicare Advantage reimbursement rates directly impact capitated revenue and margins
- Strategic partnerships with health systems accelerate entry into new geographic markets
- Provider retention and recruitment costs influence overall operating margin stability
| Net Income: 21.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -9.99 > 1.0 |
| NWC/Revenue: 16.2k% < 20% (prev 23.08%; Δ 16.2k% < -1%) |
| CFO/TA 0.00 > 3% & CFO 138.0m > Net Income 21.8m |
| Current Ratio: 1.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (130.9m) vs 12m ago 2.45% < -2% |
| Gross Margin: 9.59% > 18% (prev 0.10%; Δ 948.5% > 0.5%) |
| Asset Turnover: 0.32% > 50% (prev 152.2%; Δ -151.9% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.26 (Total Current Assets 966b - Total Current Liabilities 601b) / Total Assets 1418b |
| B: -0.11 (Retained Earnings -153b / Total Assets 1418b) |
| C: 0.00 (EBIT TTM 41.1m / Avg Total Assets 710b) |
| D: -0.25 (Book Value of Equity -152b / Total Liabilities 612b) |
| Altman-Z'' = 1.07 = BB |
| DSRI: 1.06k (Receivables 514b/388.7m, Revenue 2.25b/1.80b) |
| GMI: 1.05 (GM 9.59% / 10.09%) |
| AQI: 1.27 (AQ_t 0.31 / AQ_t-1 0.25) |
| SGI: 1.25 (Revenue 2.25b / 1.80b) |
| TATA: -0.00 (NI 21.8m - CFO 138.0m) / TA 1418b) |
| Beneish M = 868.5 (Cap -4..+1) = D |
As of June 01, 2026, the stock is trading at USD 21.51 with a total of 905,708 shares traded.
Over the past week, the price has changed by -4.99%,
over one month by -13.44%,
over three months by -10.52% and
over the past year by -5.78%.
Privia Health has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy PRVA.
- StrongBuy: 14
- Buy: 5
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31.6 | 46.9% |
P/E Trailing = 126.5294
P/E Forward = 23.6407
P/S = 1.2065
P/B = 3.5994
Revenue TTM = 2.25b USD
EBIT TTM = 41.1m USD
EBITDA TTM = 52.4m USD
Long Term Debt = 6.91b USD (estimated: total debt 9.02b - short term 2.11b)
Short Term Debt = 2.11b USD (from shortTermDebt, last quarter)
Debt = 9.03b USD (from shortLongTermDebtTotal, last quarter) + Leases 9.02m
Net Debt = -410b USD (calculated: Debt 9.03b - CCE 420b)
Enterprise Value = 2.71b USD (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = unknown (Ebit TTM 41.1m / Interest Expense TTM 0.0)
EV/FCF = 19.82x (Enterprise Value 2.71b / FCF TTM 136.8m)
FCF Yield = 5.05% (FCF TTM 136.8m / Enterprise Value 2.71b)
FCF Margin = 6.09% (FCF TTM 136.8m / Revenue TTM 2.25b)
Net Margin = 0.97% (Net Income TTM 21.8m / Revenue TTM 2.25b)
Gross Margin = 9.59% ((Revenue TTM 2.25b - Cost of Revenue TTM 2.03b) / Revenue TTM)
Gross Margin QoQ = 9.44% (prev 9.18%)
Tobins Q-Ratio = 0.00 (Enterprise Value 2.71b / Total Assets 1418b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 9.03b)
Taxrate = 32.35% (14.2m / 43.9m)
NOPAT = 27.8m (EBIT 41.1m * (1 - 32.35%))
Current Ratio = 1.61 (Total Current Assets 966b / Total Current Liabilities 601b)
Debt / Equity = 0.01 (Debt 9.03b / totalStockholderEquity, last quarter 753b)
Debt / EBITDA = -7.83k (out of range, set to none) (Net Debt -410b / EBITDA 52.4m)
Debt / FCF = -3.00k (out of range, set to none) (Net Debt -410b / FCF TTM 136.8m)
Total Stockholder Equity = 189b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.00% (Net Income 21.8m / Total Assets 1418b)
RoE = 0.01% (Net Income TTM 21.8m / Total Stockholder Equity 342b)
RoCE = 0.01% (EBIT 41.1m / Capital Employed (Equity 342b + L.T.Debt 6.91b))
RoIC = 0.00% (NOPAT 27.8m / Invested Capital 816b)
WACC = 1.99% (E(2.71b)/V(11.7b) * Re(8.60%) + D(9.03b)/V(11.7b) * Rd(0.0%) * (1-Tc(0.32)))
Discount Rate = 8.60% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 2.12%
[DCF] Terminal Value 77.97% ; FCFF base≈129.4m ; Y1≈148.3m ; Y5≈218.3m
[DCF] Fair Price = 3.28k (EV 3.29b - Net Debt -410b = Equity 414b / Shares 126.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 82.86 | EPS CAGR: 23.83% | SUE: -0.74 | # QB: 0
Revenue Correlation: 96.64 | Revenue CAGR: 13.88% | SUE: 0.25 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.24 | Chg30d=-8.42% | Revisions=-38% | Analysts=11
EPS next Quarter (2026-09-30): EPS=0.26 | Chg30d=-12.54% | Revisions=-38% | Analysts=11
EPS current Year (2026-12-31): EPS=0.94 | Chg30d=-12.16% | Revisions=-47% | GrowthEPS=-4.7% | GrowthRev=+14.3%
EPS next Year (2027-12-31): EPS=1.09 | Chg30d=-8.96% | Revisions=-29% | GrowthEPS=+15.4% | GrowthRev=+10.2%
[Analyst] Revisions Ratio: -47%